DE102005020229A1 - Verwendung von Indolin-Phenylsulfonamid-Derivaten - Google Patents

Verwendung von Indolin-Phenylsulfonamid-Derivaten Download PDF

Info

Publication number
DE102005020229A1
DE102005020229A1 DE102005020229A DE102005020229A DE102005020229A1 DE 102005020229 A1 DE102005020229 A1 DE 102005020229A1 DE 102005020229 A DE102005020229 A DE 102005020229A DE 102005020229 A DE102005020229 A DE 102005020229A DE 102005020229 A1 DE102005020229 A1 DE 102005020229A1
Authority
DE
Germany
Prior art keywords
hydrogen
diseases
alkyl
ppar
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
DE102005020229A
Other languages
German (de)
English (en)
Inventor
Elke Dr. Dittrich-Wengenroth
Helmut Dr. Haning
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Original Assignee
Bayer Healthcare AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare AG filed Critical Bayer Healthcare AG
Priority to DE102005020229A priority Critical patent/DE102005020229A1/de
Priority to PCT/EP2006/003572 priority patent/WO2006117076A1/fr
Publication of DE102005020229A1 publication Critical patent/DE102005020229A1/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
DE102005020229A 2005-04-30 2005-04-30 Verwendung von Indolin-Phenylsulfonamid-Derivaten Withdrawn DE102005020229A1 (de)

Priority Applications (2)

Application Number Priority Date Filing Date Title
DE102005020229A DE102005020229A1 (de) 2005-04-30 2005-04-30 Verwendung von Indolin-Phenylsulfonamid-Derivaten
PCT/EP2006/003572 WO2006117076A1 (fr) 2005-04-30 2006-04-19 Verwendung von indolin-phenylsulfonamid-derivaten

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102005020229A DE102005020229A1 (de) 2005-04-30 2005-04-30 Verwendung von Indolin-Phenylsulfonamid-Derivaten

Publications (1)

Publication Number Publication Date
DE102005020229A1 true DE102005020229A1 (de) 2006-11-09

Family

ID=36593821

Family Applications (1)

Application Number Title Priority Date Filing Date
DE102005020229A Withdrawn DE102005020229A1 (de) 2005-04-30 2005-04-30 Verwendung von Indolin-Phenylsulfonamid-Derivaten

Country Status (2)

Country Link
DE (1) DE102005020229A1 (fr)
WO (1) WO2006117076A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011141822A3 (fr) * 2010-05-11 2012-03-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Procédés pour induction, diagnostic prédictif et traitement de comportements affectifs par modulation des récepteurs ppar et rxr

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007341981A1 (en) * 2006-12-29 2008-07-10 The Salk Institute For Biological Studies Methods for enhancing exercise performance
WO2011150286A2 (fr) 2010-05-26 2011-12-01 Satiogen Pharmaceuticals,Inc. Inhibiteurs et satiogènes de recyclage d'acide biliaire pour traitement du diabète, de l'obésité et d'états inflammatoires gastro-intestinaux
JP6217938B2 (ja) 2011-10-28 2017-10-25 ルメナ ファーマシューティカルズ エルエルシー 小児の胆汁うっ滞性肝疾患の処置のための胆汁酸再循環阻害剤
US20130108573A1 (en) 2011-10-28 2013-05-02 Lumena Pharmaceuticals, Inc. Bile Acid Recycling Inhibitors for Treatment of Hypercholemia and Cholestatic Liver Disease
EP2968262A1 (fr) 2013-03-15 2016-01-20 Lumena Pharmaceuticals, Inc. Inhibiteurs de recyclage d'acide biliaire pour le traitement de l' sophage de barrett et du reflux gastro sophagien pathologique
CA2907230A1 (fr) 2013-03-15 2014-09-18 Lumena Pharmaceuticals, Inc. Inhibiteurs du recyclage de l'acide biliaire pour le traitement de l'angiocholite sclerosante primaire et de la maladie inflammatoire de l'intestin
AU2020221834A1 (en) 2019-02-12 2021-09-02 Mirum Pharmaceuticals, Inc. Genotype and dose-dependent response to an ASBTI in patients with bile salt export pump deficiency

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040242459A1 (en) * 2001-06-11 2004-12-02 Forrest Michael J Method for treating inflammatory diseases by administering a ppar-delta agonist
KR20040063897A (ko) * 2001-09-14 2004-07-14 툴라릭, 인코포레이티드 링크된 바이아릴 화합물
DE10229777A1 (de) * 2002-07-03 2004-01-29 Bayer Ag Indolin-Phenylsulfonamid-Derivate

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011141822A3 (fr) * 2010-05-11 2012-03-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Procédés pour induction, diagnostic prédictif et traitement de comportements affectifs par modulation des récepteurs ppar et rxr

Also Published As

Publication number Publication date
WO2006117076A1 (fr) 2006-11-09

Similar Documents

Publication Publication Date Title
DE102005020229A1 (de) Verwendung von Indolin-Phenylsulfonamid-Derivaten
EP2697191B1 (fr) Dérivés ramifiés de l'acide 3-phénylpropionique et leur utilisation
EP2635577B1 (fr) 6-fluoro-1h-pyrazolo[4,3-b]pyridines substituées et leur utilisation
DE60315796T2 (de) Hydroxynaphthyridinoncarbonsäureamide, die sich als inhibitoren der hiv-integrase eignen
EP2635576B1 (fr) Carbamates substitués par des benzyles et leur utilisation
WO2010003475A2 (fr) Nouveaux dérivés de pyrrolidine utilisés comme inhibiteurs de la metap-2
EP2627631A1 (fr) Pyrrolidinones en tant qu'inhibiteurs de metap-2
DE102009046115A1 (de) Substituierte 3-Phenylpropansäuren und ihre Verwendung
CA2819880A1 (fr) Acides carboxyliques 1-benzylcycloalkyle substitues et leur utilisation
EP3325013B2 (fr) Stimulateurs / activateurs de guanylate cyclase soluble en combinaison avec un inhibiteur de l'endopeptidase neutrale (nep) et un antagonist d'angiotensin ii et son utilisation
EP3030562A1 (fr) Pyrazolo[1,5-a]pyridine-3-carboxamides substitués et leur utilisation
EP2024361A1 (fr) 3-tétrazolylindazoles et 3-tétrazolylpyrazolopyridines et leur utilisation
EP3030564A1 (fr) Imidazo[1,2-a]pyrazincarboxamides substitués et leur utilisation
EP3119778A1 (fr) Imidazo[1,2-a]pyridine-carboxamides substitués et leur utilisation
DE10300099A1 (de) Indol-Phenylsulfonamid-Derivate
DE102006043519A1 (de) 4-Phenoxynikotinsäure-Derivate und ihre Verwendung
EP1966218B1 (fr) Nouveaux derives de furopyrimidines a substitution cyclique et leur utilisation pour traiter des maladies cardiovasculaires
DE102005020230A1 (de) Verwendung von Indolin-Phenylsulfonamid-Derivaten
DE2123318A1 (de) Aminoderivate von Pyrazolopyridincarbonsäuren, deren Estern und Salzen, Verfahren zu ihrer Herstellung und ihre Verwendung
WO2008131859A2 (fr) Utilisation de dérivés de furopyrimidine à substitution cyclique dans le traitement de l'hypertonie artérielle pulmonaire
WO2016023885A1 (fr) Quinoline-4-carboxamides substitués et leur utilisation
DE3242442A1 (de) Benzylidenderivate, verfahren zu ihrer herstellung und sie enthaltende arzneimittel
DE102010062544A1 (de) Substituierte 1-Benzylcycloalkylcarbonsäuren und ihre Verwendung
DE102012200356A1 (de) Substituierte Imidazopyridine und Imidazopyridazine und ihre Verwendung
DE102010030187A1 (de) 4-Cyan-2-sulfonylphenyl)pyrazolyl-substituierte Pyridinone und Pyrazinone und ihre Verwendung

Legal Events

Date Code Title Description
8130 Withdrawal